Zim Laboratories Ltd

Zim Laboratories Investor Presentation: Key Takeaways

Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.

Zim Laboratories Q2 FY27 Results: Net Loss of ₹2 Cr, Loss Widens

Zim Laboratories Ltd reported revenue from operations of ₹105.4 Cr (+18.8% YoY) and a net loss of ₹2 Cr for Q2 FY27.

Key figure

Net loss ₹2 Cr

Zim Laboratories Board Meeting Date

Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.

Zim Laboratories Regulatory Approval

Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.

From

Therapeutic Goods Administration (TGA), Australia

Zim Laboratories Credit Rating

CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.

Zim Laboratories Other Announcement

Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.

Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr

ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.

Value

₹14,04,640 Cr

Zim Laboratories Merger & Restructuring

ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.

Zim Laboratories Acquisition Worth ₹1.56 Cr

ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.

Value

₹1.56 Cr

Zim Laboratories Merger & Restructuring Worth ₹2.38 Cr

Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.

Value

₹2.38 Cr

Zim Laboratories Other Announcement

A periodic shareholding pattern filing for Zim Laboratories Ltd for the quarter ended March 31, 2026, disclosing promoter and public shareholding details.

Zim Laboratories Investor Presentation: Key Takeaways

Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.

Call

Guides 32% growth

Zim Laboratories Annual General Meeting

Zim Laboratories Limited has announced the successful passing of Special Resolutions through a postal ballot, approving the remuneration structure for its Managing and Whole-Time Directors.